NCT04078386View on ClinicalTrials.gov

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

June 23, 2021

Study Completion Date

October 26, 2021

Conditions
Primary Sjögren's Syndrome
Interventions
BIOLOGICAL

Placebo

Patients received the test group Placebo weekly administered subcutaneously for 24 times.

BIOLOGICAL

RC18 240 mg

Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.

BIOLOGICAL

RC18 160 mg

Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.

Trial Locations (1)

264006

Remegen,Ltd., Yantai

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04078386 - A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter